BRISTOL-MYERS SQUIBB COMPANY Other Comprehensive Income (Loss), Reclassification Adjustment for Sale of Securities Included in Net Income, Net of Tax (Deprecated 2012-01-31)
BRISTOL-MYERS SQUIBB COMPANY (BMY) reported Other Comprehensive Income (Loss), Reclassification Adjustment for Sale of Securities Included in Net Income, Net of Tax (Deprecated 2012-01-31) of $2.00 million for the 3-month period ending 2012-06-30, per its 10-Q filed 2012-07-25.
Discontinued › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeReclassificationAdjustmentForSaleOfSecuritiesIncludedInNetIncomeNetOfTax · last filed 2012-07-25
- BRISTOL-MYERS SQUIBB COMPANY other comprehensive income (loss), reclassification adjustment for sale of securities included in net income, net of tax (deprecated 2012-01-31) for the quarter ending 2012-06-30 was $2.00M.
- BRISTOL-MYERS SQUIBB COMPANY other comprehensive income (loss), reclassification adjustment for sale of securities included in net income, net of tax (deprecated 2012-01-31) for the quarter ending 2012-03-31 was -$10.00M.
- BRISTOL-MYERS SQUIBB COMPANY other comprehensive income (loss), reclassification adjustment for sale of securities included in net income, net of tax (deprecated 2012-01-31) for the quarter ending 2009-12-31 was -$6.00M.
- BRISTOL-MYERS SQUIBB COMPANY other comprehensive income (loss), reclassification adjustment for sale of securities included in net income, net of tax (deprecated 2012-01-31) for the quarter ending 2009-09-30 was $0.00.
- BRISTOL-MYERS SQUIBB COMPANY other comprehensive income (loss), reclassification adjustment for sale of securities included in net income, net of tax (deprecated 2012-01-31) for fiscal 2009 was -$6.00M.
- BRISTOL-MYERS SQUIBB COMPANY other comprehensive income (loss), reclassification adjustment for sale of securities included in net income, net of tax (deprecated 2012-01-31) for fiscal 2008 was -$181.00M.
- BRISTOL-MYERS SQUIBB COMPANY other comprehensive income (loss), reclassification adjustment for sale of securities included in net income, net of tax (deprecated 2012-01-31) for fiscal 2007 was $0.00.
| Period end | Other Comprehensive Income (Loss), Reclassification Adjustment for Sale of Securities Included in Net Income, Net of Tax (Deprecated 2012-01-31) 3 month | Other Comprehensive Income (Loss), Reclassification Adjustment for Sale of Securities Included in Net Income, Net of Tax (Deprecated 2012-01-31) 6 month | Other Comprehensive Income (Loss), Reclassification Adjustment for Sale of Securities Included in Net Income, Net of Tax (Deprecated 2012-01-31) 9 month | Other Comprehensive Income (Loss), Reclassification Adjustment for Sale of Securities Included in Net Income, Net of Tax (Deprecated 2012-01-31) 12 month |
|---|---|---|---|---|
| 2012-06-30 | $2.00M 10-Q · filed 2012-07-25 | -$8.00M 10-Q · filed 2012-07-25 | ||
| 2012-03-31 | -$10.00M 10-Q · filed 2012-04-26 | |||
| 2009-12-31 | -$6.00M derived: 10-K 12 month − 10-Q 9 month · filed 2010-02-19 | -$6.00M derived: sum of 2 quarters · filed 2010-02-19 | -$6.00M 10-K · filed 2010-02-19 | |
| 2009-09-30 | $0.00 10-Q · filed 2009-10-22 | $0.00 10-Q · filed 2009-10-22 | ||
| 2008-12-31 | -$27.00M derived: 10-K 12 month − 10-Q 9 month · filed 2010-02-19 | -$181.00M derived: sum of 2 quarters · filed 2010-02-19 | -$181.00M 10-K · filed 2010-02-19 | |
| 2008-09-30 | -$154.00M 10-Q · filed 2009-10-22 | -$154.00M 10-Q · filed 2009-10-22 | ||
| 2007-12-31 | $0.00 10-K · filed 2010-02-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |